Form 8-K - Current report:
SEC Accession No. 0000950170-25-069195
Filing Date
2025-05-12
Accepted
2025-05-12 16:10:02
Documents
13
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnth-20250512.htm   iXBRL 8-K 50971
2 EX-99.1 dnth-ex99_1.htm EX-99.1 255772
3 GRAPHIC img85518887_0.jpg GRAPHIC 12755
  Complete submission text file 0000950170-25-069195.txt   494622

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dnth-20250512.xsd EX-101.SCH 57693
15 EXTRACTED XBRL INSTANCE DOCUMENT dnth-20250512_htm.xml XML 4698
Mailing Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036
Business Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036 929-999-4055
Dianthus Therapeutics, Inc. /DE/ (Filer) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38541 | Film No.: 25934869
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)